Exchange: NYSE·Updated 06:31 AM EDT
News
all
press releases
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire NEW YORK, Aug. 6, 2026 Achieved $31.7 million in second quarter 2026 total revenue, including $23.2 million in...
PR Newswire
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI (taletrectinib) in Advanced ROS1-Positive...
PR Newswire
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.
Zacks
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?
Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?
The consensus price target hints at a 94.3% upside potential for Nuvation Bio (NUVB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 PR Newswire NEW YORK, July 22, 2026 NEW YORK, July 22, 2026 /PRNewswire/ -- Nuvation...
PR Newswire
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?
Nuvation Bio (NUVB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks
NUVB Stock Is Soaring Today — Why RBC Sees $3B Opportunity In Nuvation Bio's Brain Cancer Drug
According to TheFly, RBC Capital analyst Leonid Timashev said the updated long-term follow-up data reinforce safusidenib's competitive profile in IDH1-mutant glioma.
Stocktwits
Why Is Nuvation Bio Stock Gaining Monday?
Nuvation Bio reports positive long-term Phase 2 safusidenib data for glioma patients and expands its clinical trial pipeline.read more...
Benzinga

Advertisement|Remove ads.